
Partnership hopes to make progress on pancreatic cancer with research network
TORONTO — Kevin Rabishaw had the classic signs — persistent back and abdominal pain, sudden onset of diabetes and pronounced weight loss — but as too often happens with pancreatic cancer, his symptoms weren’t diagnosed early enough to make a difference.
Despite having surgery to remove a large tumour on his pancreas, followed by rounds of chemotherapy, Rabishaw died last month at age 57, just nine months after his diagnosis.
It is an all too familiar story for health professionals and cancer advocacy groups who deal with this malignancy, the fourth deadliest cancer affecting Canadians, which accounts for six per cent of all cancer deaths in the country.
Yet despite having such a lethal profile — only seven per cent of patients live five years from diagnosis — pancreatic cancer is among the most poorly funded when it comes to research dollars, with only about two per cent of all monies raised for cancer going to this type of tumour.